European health tech venture studio M2care has announced the completion of its fundraising with the participation of a new institutional investor, the French Tech Accélération 2 (FTA2) fund, managed by Bpifrance on behalf of the French government.
This brings the total amount raised to €26 million, alongside existing investors Mérieux Développement, Institut NAOS des Sciences de la Vie, Crédit Agricole Centre-Est, and Family Offices.
This new operation will finance the creation and development of eight innovative projects in the healthcare sector.
As a European Healthtech venture studio, M2care establishes, develops and finances early-stage innovative ventures, together with the founders.
Acting a link between academia, investors and industry, M2care co-founds companies with the support of an experienced team of entrepreneurs ‘in residence’ and a unique international networ
Florence Thueux, President of M2care, said: “I am delighted that France 2030’s French Tech Acceleration 2 fund has invested in our studio.
“Bpifrance is a leading player whose strong support will help to bring healthcare innovations to patients and into the market.
“I would like to sincerely thank Pierre Gillet, Océane Fleury, and the Bpifrance team for the trust they have placed in us.”
M2care has already invested in three projects, currently being co-developed alongside the founders.
Previa Medical has designed a digital medical device intended to predict and prevent medical emergencies in hospitals;
Meanwhile, TheraSonic is developing a medical device based on the use of ultrasound and intended to improve the treatment of brain diseases;
Finally, Rhovica Neuroimaging is developing a ventricular drainage catheter with integrated sensors to optimise the treatment of emergency patients at risk of increased intracranial pressure.
M2care is advancing projects primarily in cardiology, dermatology, ophthalmology and neurology, and is preparing to launch a fourth project within the studio.
Carsten Laue, General Manager of M2care, said: “We are very pleased that France 2030’s FTA 2 fund, managed on behalf of the French government by Bpifrance, is supporting our venture studio and helping to create pioneering health tech startups.”
Pierre Gillet, Investment Director at Bpifrance, added: “By investing in M2care, we are reaffirming our commitment to strengthening our technological sovereignty in healthcare.
“We are delighted to contribute to this effort on behalf of the French government.”
